Recent progress in molecular biology has enabled us to better understand the molecular mechanism underlying pathogenesis of human malignancy including lung cancer, the advent of therapies based on mechanisms that target critical molecular pathways of tumors has evoked considerable interest. The therapeutic index is high, and optimally effective treatment can be achieved at a dose below the maximal tolerated dose,giving us a better understanding of the human lung cancer. This review focuses on the advance of targeted therapy for the first-line, second-line treatment or the maintenance treatment of non-small cell lung cancer.

Lung cancer is the most common cancer and the leading cause of cancer-related deaths in the world. More than 50 % of advanced NSCLC are diagnosed in patients older than age 65 years. Aging is inextricably associated with decreases in marrow reserve, drug clearance, and lean body mass. Elderly cancer patients often present with medical and physiologic challenges that make the selection of their optimal treatment daunting. This article reviews the progress in diagnosis and treatment of lung cancer in the elderly in recent years.

The results of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC)had reached a plateau.Targeted therapy is the key to improving efficacy.In the last 5 years the epidermal growth factor receptor(EGFR)has emerged as one of the most important targets for drug development in oncology.Small molecules that inhibit the tyrosine kinase(TK)domain of EGFR have become new critical weapons in the treatment of NSCLC.Monoclonal antibodies targeting the external domain of EGFR have been shown to have clinical benefit when combined with chemotherapy.Recent data suggest that multitargeted inhibitors might have greater activity owing to their ability to simultaneously block key signaling pathways.Preliminary results of such agents in clinical trials shows that they have a well-tolerated toxicity profile,and might have a promising value in the treatment of advanced non-small-cell lung cancer.

The performance status(PS)≥2 patients with non-small cell lung cancer(NSCLC) are short of effective management.The phase Ⅱ/Ⅲ clinical trails of target therapy of anti EFGR of VEGFR have already got promise results.This article expatiates the actuality and development of the chemotherapy and novel target therapy for the PS≥2 patients with NSCLC.

3 months. Female gender, adenocarcinoma history, non-smoking history, good PS and the presence of multiple lung metastases are associated with improved responsiveness to Gefitinib. Reflecting the results of previous clinical trials, the reports indicate that Gefitinib is generally well tolerated by Asian patients. The incidence of interstitial lung disease appears to be higher in Japanese than non-Japanese patients, although the reason for this is not clear. Recent findings regarding Erlotinib and other targeted therapy among Asian patients are discussed.

OBJECTIVE: To study the protective effect of 3-acetyl- 4-acetoxy-2-benzoxazolone on liver injury induced by carbon tetrachloride (CCl4) in mice. METHODS: The serum activities of ALT and AST and the levels of MDA, SOD and GSH in liver tissue were measured in the model of acute liver injury induced by intraperitoneal injection 0.15% CCl4 and hepatic histological changes were observed by optical microscope. RESULTS: Compared with control group, the serum ALT, AST and the liver tissue MDA activities were significantly lowered, the levels of SOD and GSH in liver tissue were increased obviously. Histological results showed that 3-acetyl- 4-acetoxy-2-benzoxazolone could ameliorate histological damages induced by CCl4 in mice. CONCLUSION: 3-Acetyl-4-acetoxy-2-benzoxazolone exhibits protective effects on experimental hepatic injury.

As a hot topic, biomarkers can provide reliable evidence for the individualized treatment of non-small cell lung cancer. With the further study of molecular biology and development of new drugs,biomarkers have shown a broad prospect in clinical application. Combining with the research in recent years,this review describes the progress in biomarkers for non-small-cell lung cancer.

A platinum-based doublet with a third-generation agent represents the standard first-line treatment for advanced non-small cell lung cancer patients with good performance status (PS). Traditional chemotherapy provides response rates of 20 %-40 % and a median survival of 8-10 months. In an attempt to improve its outcome, alternative schedules have been proposed, namely sequential, alternating, and maintenance therapy. Sequential chemotherapy with a platinum-based doublet followed by a single agent is feasible in patients with good PS; The use of sequential single agents is an option for elderly and frail patients unsuitable for a platinum-based combination. Based on trials published so far, it is unlikely that an alternating chemotherapy strategy will be proved superior to standard chemotherapy in patients with good PS.Consolidation chemotherapy may provide additional benefit for patients achieving disease control after standard first-line chemotherapy.

This article discussed the necessity and research significance of TCM literature digitization from the aspects of features of TCM literature and connotation and advantages of literature digitization. It introduced the research background of TCM literature digitization by using the examples of domestic and foreign digital libraries and digitized periodicals, expounded the research status of TCM modern and ancient literature digitization, elaborated the research condition of TCM ancient literature digitization, and analyzed the existing problems and provided suggestions.